reports
Eledon Pharmaceuticals to Present at the 18th Congress of the Internat...
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland. Details are as follows: Plenary Session: Immunosuppression, Immune Monitoring, Anti-CD154* Pathway...
Preformed Line Products Co: 3 directors
Three Directors at Preformed Line Products Co sold 7,904 shares at 188.370USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conf...
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Friday, September 5, 2025, at 9:10 a.m. ET (6:10 a.m. PT). To register in advance for the fireside chat webcast, sign up . A webcast replay will be accessible following the live session on the Company’s website under . About Eledon Pharm...
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Finan...
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2025...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Te...
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation Data from patients who remained on tegoprubart for a year showed overall mean 12-month eGFR of approximately 68 mL/min/1.73 m² post-transplant Preliminary iBox data, a key biomarker of kidney function and immunologic response, supports that tegoprubart may improve 5-year graft survival vs. current standard of care Tegoprubart continues to be well tolerated with no cases of death, graft loss, drug related tremor, or new-onset diabetes Conference call to be ...
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Da...
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025 IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplanta...
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Te...
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025 IRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation will be presented at the World Transplant Congress (WTC) taking place in San Francisco from August 2-6, 2025. The oral pres...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
AVAV AEROVIRONMENT INC.
KFS KINGSWAY FINANCIAL SERVICES
PAYS PAYSIGN INC
PRCH PORCH GROUP INC (A)
SPNT SIRIUSPOINT LTD
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
OSCR OSCAR HEALTH
JOBY JOBY AVIATION INC
COIN COINBASE GLOBAL INC
EVEX EVE HOLDING INC
GCT GIGACLOUD TECHNOLOGY INC
CRBG COREBRIDGE FINANCIAL INC.
SGHC SUPER GROUP (SGHC) LIMITED
RDW REDWIRE CORP
DAVE DAVE INC
GRALV GRAIL INC.
SMCI SUPER MICRO COMPUTER INC.
EVTL VERTICAL AEROSPACE LTD.
ANET ARISTA NETWORKS INC
OWLT OWLET INC
ESP BROMPTON ENERGY SPLIT CORP
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York Cit...
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET. The event will feature members of Eledon’s executive team and the following leading experts in transplantation: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minne...
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financ...
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025 IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported...
- Wedbush Research
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VLY VALLEY NATIONAL BANCORP
TCBI TEXAS CAPITAL BANCSHARES INC.
RF REGIONS FINANCIAL CORPORATION
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
NYCB NEW YORK COMMUNITY BANCORP INC.
KEY KEYCORP
HMST HOMESTREET INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
COLB COLUMBIA BANKING SYSTEM INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
BKU BANKUNITED INC.
BANC BANC OF CALIFORNIA INCORPORATED
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
SLM SLM CORP
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
AX AXOS FINANCIAL INC.
LC LENDINGCLUB CORP
AFRM AFFIRM HOLDINGS
BUR BURFORD CAPITAL
UPST UPSTART HOLDINGS
SOFI SOFI TECHNOLOGIES INC
PGY PAGAYA TECHNOLOGIES LTD
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Opera...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantati...
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healt...
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up . A webcast replay will be accessible following the live session on the Company’s website under ....
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component o...
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L) with potential to improve both safety and efficacy compared to standard of care immunosuppression regimens IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasd...
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Ca...
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 1:00 p.m. ET (10:00 a.m. PT). To register in advance for the presentation webcast, sign up . A webcast replay will be ...
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provi...
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppress...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third ...
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Announced oversubscribed $85 million underwritten offering, with proceeds expected to ...
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugur...
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Guggenheim Securities Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 1:30 p.m. ET (10:30 a.m. PT). To register in advance for the presentation webcast, sign up . A webcast replay will be accessible following the live sess...
- Wedbush Research
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WLDN WILLDAN GROUP
WDC WESTERN DIGITAL CORPORATION
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VLY VALLEY NATIONAL BANCORP
TCBI TEXAS CAPITAL BANCSHARES INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RF REGIONS FINANCIAL CORPORATION
PPBI PACIFIC PREMIER BANCORP INC.
PEGA PEGASYSTEMS INC.
PB PROSPERITY BANCSHARES INC.(R)
OHI OMEGA HEALTHCARE INVESTORS INC.
NYCB NEW YORK COMMUNITY BANCORP INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
KEY KEYCORP
IMAX IMAX CORPORATION
HMST HOMESTREET INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
GOOGL ALPHABET INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
GERN GERON CORP.
FRC FIRST REPUBLIC BANK
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
EGP EASTGROUP PROPERTIES INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
CTRE CARETRUST REIT INC
COLB COLUMBIA BANKING SYSTEM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
CAKE CHEESECAKE FACTORY INCORPORATED
BMRN BIOMARIN PHARMACEUTICAL INC.
BKU BANKUNITED INC.
BANC BANC OF CALIFORNIA INCORPORATED
ASND ASCENDIS PHARMA A/S SPONSORED ADR
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
SLM SLM CORP
TSC TRISTATE CAPITAL HOLDINGS INC
PTGX PROTAGONIST THERAPEUTICS
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
VICI VICI PROPERTIES INC
SE SEA ADS
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AX AXOS FINANCIAL INC.
SAFE SAFEHOLD INC.
LC LENDINGCLUB CORP
IDYA IDEAYA BIOSCIENCES
KROS KEROS THERAPEUTICS
U UNITY SOFTWARE
RZLT REZOLUTE
LSEA LANDSEA HOMES CORP (A)
PLTR PALANTIR TECHNOLOGIES
WOOF PETCO HEALTH AND WELLNESS
RBLX ROBLOX
FHTX FOGHORN THERAPEUTICS
SOFI SOFI TECHNOLOGIES INC
APP APPLOVIN CORP
MLTX MOONLAKE IMMUNOTHERAPEUTICS
EWTX EDGEWISE THERAPEUTICS INC
GETY GETTY IMAGES HOLDINGS INC
SKLZ SKILLZ INC
- Brian Violino
- David Chiaverini
- Sydnie Rohme
USB U.S. BANCORP
ZION ZIONS BANCORPORATION N.A.
WTFC WINTRUST FINANCIAL CORPORATION
WBS WEBSTER FINANCIAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
VLY VALLEY NATIONAL BANCORP
TCBI TEXAS CAPITAL BANCSHARES INC.
RF REGIONS FINANCIAL CORPORATION
PPBI PACIFIC PREMIER BANCORP INC.
PB PROSPERITY BANCSHARES INC.(R)
NYCB NEW YORK COMMUNITY BANCORP INC.
KEY KEYCORP
HMST HOMESTREET INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
HAFC HANMI FINANCIAL CORPORATION
FRC FIRST REPUBLIC BANK
FITB FIFTH THIRD BANCORP
FHN FIRST HORIZON CORPORATION
FFWM FIRST FOUNDATION
EWBC EAST WEST BANCORP INC.
CVBF CVB FINANCIAL CORP.
CUBI CUSTOMERS BANCORP INC.
COLB COLUMBIA BANKING SYSTEM INC.
CFG CITIZENS FINANCIAL GROUP INC.
CATY CATHAY GENERAL BANCORP
BKU BANKUNITED INC.
BANC BANC OF CALIFORNIA INCORPORATED
CFR CULLEN/FROST BANKERS INC.
BOKF BOK FINANCIAL CORPORATION
CMA COMERICA INCORPORATED
SLM SLM CORP
TSC TRISTATE CAPITAL HOLDINGS INC
HOPE HOPE BANCORP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
AX AXOS FINANCIAL INC.
LC LENDINGCLUB CORP
SOFI SOFI TECHNOLOGIES INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.